论文部分内容阅读
目的探讨P-糖蛋白(P-gp)和谷胱甘肽转移酶(GST-π)在新辅助化疗乳腺癌组织的表达及临床意义。方法采用免疫组织化学方法检测100例乳癌患者新辅助化疗前后肿瘤组织中P-gp及GST-π的表达,并与疗效作相关性分析。结果新辅助化疗总有效率79%,P-gp、GST-π阳性者化疗有效率分别为69.04%和77.08%,阴性者分别为86.20%(P<0.05)和80.76%(P>0.05)。P-gp在化疗前后的阳性表达率分别为41.75%和64.83%,差异有统计学意义(P<0.05);GST-π在化疗前后阳性表达率分别为49.45%和54.94%,差异无统计学意义(P>0.05)。结论新辅助化疗后P-gp表达显著升高,P-gp对乳腺癌新辅助化疗疗效有一定预测价值。
Objective To investigate the expression and clinical significance of P-glycoprotein (P-gp) and glutathione transferase (GST-π) in neoadjuvant chemotherapy of breast cancer. Methods Immunohistochemistry was used to detect the expression of P-gp and GST-π in 100 cases of breast cancer before and after neoadjuvant chemotherapy, and the correlation was analyzed with the curative effect. Results The total effective rate of neoadjuvant chemotherapy was 79%. The effective rates of chemotherapy with P-gp and GST-π were 69.04% and 77.08%, respectively. The negative rates were 86.20% (P <0.05) and 80.76% (P> 0.05) respectively. The positive rates of P-gp before and after chemotherapy were 41.75% and 64.83%, respectively, with significant difference (P <0.05). The positive rates of GST-π before and after chemotherapy were 49.45% and 54.94%, respectively, with no significant difference Significance (P> 0.05). Conclusions The expression of P-gp in neoadjuvant chemotherapy is significantly increased, and P-gp may have some predictive value for neoadjuvant chemotherapy in breast cancer.